GlycoMimetics to Present New Preclinical Data on Its E-selectin-CXCR4 Dual Antagonist at AACR Annual Meeting 2016
Data bolsters scientific rationale for clinical evaluation of GMI-1359 in AML patients harboring aberrant FLT3 and in patients with pancreatic cancer
"Our data provides additional preclinical support for initiating
clinical trials of GMI-1359 in both FLT3 mutated AML and pancreatic
cancer. GMI-1359's ability to disrupt the tumor microenvironment and
known pathways of cancer cell trafficking has great potential to improve
survival in some of the most challenging cancers," said
The AACR presentations from
-
Steele, M.M., et al. "A Small Molecule Glycomimetic Antagonist of
E-Selectin and CXCR4 (GMI-1359) Delays Pancreatic Tumor Metastasis and
Significantly Alters the Pancreatic Tumor Microenvironment"
[MiniSymposium: Immunomodulation in cancer. MS.TB06.01,
Sunday, April 17, 2016 ,4:15-6:15 p.m. Central Time ] Abstract 902 -
Zhang, W., et al. "Targeting E-selectin/CXCR4 with GMI-1359
Effectively Mobilizes Bone Marrow Leukemia Cells and Enhances FLT3
Inhibitor-induced Anti-leukemia Efficacy in a Murine Acute Myeloid
Leukemia Model" [Hematological Environment - Poster Session
PO.TB06.04,
Tuesday, April 19, 2016 ,8:00 a.m.-12:00 p.m. Central Time ] Abstract 3284
About
View source version on businesswire.com: http://www.businesswire.com/news/home/20160317005447/en/
Investor:
sannes@annesassociates.com
or
Media:
jamielacey@presscommpr.com
Source:
News Provided by Acquire Media